NYSE - Delayed Quote USD

Novo Nordisk A/S (NVO)

Compare
118.03 +0.22 (+0.19%)
At close: 4:00 PM EDT
117.85 -0.18 (-0.15%)
After hours: 4:49 PM EDT
Loading Chart for NVO
DELL
  • Previous Close 117.81
  • Open 116.95
  • Bid 117.00 x 900
  • Ask 117.90 x 900
  • Day's Range 116.44 - 118.06
  • 52 Week Range 92.94 - 148.15
  • Volume 2,827,921
  • Avg. Volume 4,117,312
  • Market Cap (intraday) 523.098B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 40.01
  • EPS (TTM) 2.95
  • Earnings Date Nov 6, 2024
  • Forward Dividend & Yield 1.45 (1.23%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 142.56

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com

69,260

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVO

View More

Related Videos: NVO

What is post-earnings announcement drift and why it matters

With the third quarter earnings season underway, Catalyst Funds senior portfolio manager David Miller sits down with Brad Smith on Wealth! to talk about why post-earnings announcement drift is so important to his earnings season strategy. Miller says he looks “for companies where they've demonstrated clear post-earnings announcement drift.” Post-earnings announcement drift, or PEAD, is the tendency of a stock to drift in the direction of earnings for a period after the results are announced. PEAD is “one of the most powerful anomalies in finance, and basically what it says is that companies that have historically beat earnings in a significant way consistently tend to continue to beat earnings, and their stocks continue to do well. [The] same goes for those that have missed earnings consistently. They continue to do poorly. So [it's] not a surprising concept that winners tend to continue winning and the losers tend to continue losing.” The portfolio manager says there are a few standout companies and industries where a PEAD has consistently occurred in recent quarters. He names the healthcare sector with companies like Novo Nordisk (NVO) climbing on weight loss drug popularity. Miller also highlights the networking space, including Arista Networks (ANET), as well as fintech companies like Visa (V) and Mastercard (MA). To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Naomi Buchanan.

Performance Overview: NVO

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVO
15.35%
OMX Copenhagen 25 Index
6.68%

1-Year Return

NVO
16.83%
OMX Copenhagen 25 Index
14.34%

3-Year Return

NVO
139.75%
OMX Copenhagen 25 Index
2.32%

5-Year Return

NVO
380.60%
OMX Copenhagen 25 Index
70.45%

Compare To: NVO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVO

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    522.12B

  • Enterprise Value

    521.30B

  • Trailing P/E

    40.08

  • Forward P/E

    29.41

  • PEG Ratio (5yr expected)

    1.81

  • Price/Sales (ttm)

    13.96

  • Price/Book (mrq)

    31.83

  • Enterprise Value/Revenue

    13.82

  • Enterprise Value/EBITDA

    26.63

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    34.84%

  • Return on Assets (ttm)

    22.80%

  • Return on Equity (ttm)

    88.57%

  • Revenue (ttm)

    258B

  • Net Income Avi to Common (ttm)

    89.9B

  • Diluted EPS (ttm)

    2.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    62.65B

  • Total Debt/Equity (mrq)

    50.71%

  • Levered Free Cash Flow (ttm)

    54.49B

Research Analysis: NVO

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 68.06B
Earnings 20.05B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

85.23 Low
142.56 Average
118.03 Current
166.48 High
 

Company Insights: NVO

Research Reports: NVO

View More
  • Global Stocks Priced at Discount to U.S. Stocks

    As worldwide markets are challenged in an environment of higher interest rates, conflict in the Middle East, and the lingering battle between Russia and Ukraine, one thing has not changed: U.S. stocks are more expensive than global stocks. And with the large run-up in stock prices in late 2023 and the first half of 2024, U.S. stocks are even more expensive. Consider P/E ratios. The trailing P/E ratio on the S&P 500 is 28, above the global average of 14 and well above the 6-12 average P/Es for emerging markets stocks. A review of yields tells a similar story. The current dividend yield for the S&P 500 is 1.2%, versus the global average of 2.8% and Asian, Australian and Latin American yields of 3%-6%. The foreign region that does not completely fit the pattern is the Middle East. The average P/E on a Saudi Arabian stock is a relatively high 17. This can be attributed to high oil prices. Taking a step back, one reason investors generally are willing to pay a higher price for North American securities is the transparency of the U.S. financial system as well as the liquidity of U.S. markets. What's more, global returns can be volatile across individual countries, given currency, security, political, and geopolitical risks. Indeed, U.S. stocks (ETF SPY) have outperformed EAFE (ETF EFA) over the past year as well as over the past five years. Even so, we recommend that growth investors have approximately 5%-10% of their equity allocations in international stocks to take advantage of the value, and we have been adding global stocks to our Universe of Coverage.

     
  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, playing the long game on commercial turbine engines; making the case for integrated oils despite the headlines; watching where Prudential tilts; and Nike, Novo Nordisk, and Zhejiang Supor.

     
  • Novo Nordisk: Disappointing Early Data for Novel Oral Obesity Drug

    With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

    Rating
    Price Target
     
  • Novo Nordisk: Disappointing Early Data for Novel Oral Obesity Drug

    With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

    Rating
    Price Target
     

People Also Watch